Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT-101 in Major Depressive Disorder
NCT07610473Phase 2Recruiting
- Sponsor
- Draig Therapeutics
- Start
- May 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing DT-101 with Placebo (2 arms). Primary endpoint: Montgomery Åsberg Depression Rating Scale at 56 days. Started May 2026; status: recruiting.
02
Drugs
DT-101
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07610473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610473.